The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison.
Tibor M Brunt, Raymond J.m. Niesink
Drug Testing and Analysis September 2011 DOI: 10.1002/dta.323 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Illicit drug samples submitted at DIMS testing facilities in the Netherlands |
| Key findings | The review describes the Drug Information and Monitoring System (DIMS), which has collected more than 100,000 illicit drug samples over nearly two decades to prevent health hazards from unexpected substances. It overviews monitoring results for ecstasy, amphetamine, and cocaine markets, and for the first time hallucinogens, and discusses drug monitoring from policy, prevention, and user perspectives. |
Abstract
The Ministry of Health in the Netherlands has made illicit drug testing for drug users possible since the 1990s, in order to prevent serious health hazards associated with unexpected dangerous substances. This system of illicit drug testing is called the Drug Information and Monitoring System (DIMS). In nearly two decades, more than 100 000 drug samples have been handed in at DIMS testing facilities. This review describes the DIMS methodology and overviews results of the three main psychostimulant drug markets that have been monitored, i.e. ecstasy, amphetamine (speed), and cocaine. Additionally, monitoring results of hallucinogens are also described for the first time. For comparison, alternative international monitoring systems are described briefly alongside some of their results. Finally, drug monitoring is discussed from the perspectives of policy, prevention, and the drug users themselves.
Citations in the library
Cited by 19
- New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Testing and Analysis 2014
- Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug and Alcohol Dependence February 1, 2015
- The detection and prevention of unintentional consumption of DOx and 25x‐NBOMe at Portugal's Boom Festival Human Psychopharmacology: Clinical and Experimental May 1, 2017
- Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands. Addiction April 1, 2017
- Changes in Online Psychoactive Substance Trade via Telegram during the COVID-19 Pandemic. European Addiction Research 2021
and 14 more in the library
Cites 10
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Journal of Neurology, Neurosurgery, and Psychiatry June 1, 2000
- The content of ecstasy tablets: implications for the study of their long‐term effects Addiction December 1, 2002
- Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002 Human Psychopharmacology: Clinical and Experimental September 19, 2003
- Fatalities Caused by the MDMA-Related Drug Paramethoxyamphetamine (PMA) Journal of Analytical Toxicology October 1, 2001
and 5 more in the library